DigiSight Technologies Inc.
Mobile apps for ophthalmology
This article was originally published in Start Up
DigiSight Technologies Inc.'s cloud-based Paxos platform enables patients with acute ophthalmic conditions to self-administer 10 functional tests, ranging from visual acuity to color discrimination, using an application on a smartphone, tablet or other mobile device.
You may also be interested in...
SK Bioscience has received the world’s first approval of its in-house developed recombinant protein COVID-19 vaccine SKYCovione (GBP510), in its home market of South Korea, two years after it began development. Strong support from the domestic government and international cooperation helped pave the way.
Can-Fite’s A3AR agonist was inferior to Amgen’s Otezla by most efficacy measures, while Bristol Myers Squibb’s competing deucravacitinib is closer to approval and did beat Otezla.
The company’s lipid nanoparticle technology can deliver mRNA, gene editing and other cargoes to multiple cell and organ types. ReCode aims to expand its pipeline beyond lung diseases.